Experience

RAPT Therapeutics

• Biotechnology Research
• 100 - 200 Employee

• Senior Vice President of Quantitative and Computational Biology

  • Feb 2020 - Present

• Vice President of Quantitative and Computational Biology

  • Jan 2016 - Present

  San Francisco Bay Area At RAPT, our focus is on developing drugs that target key drivers of the immune system to overcome cancer or subdue aberrant inflammation. Our quantitative biology team is developing and running high-quality assays in both biochemical and cell-based formats. We provide decision-driving structure-activity-relationship (SAR) data for our team of medicinal chemists throughout the drug discovery process. We develop assays to measure pharmacodynamic (PD) response to our drugs during preclinical… Show more At RAPT, our focus is on developing drugs that target key drivers of the immune system to overcome cancer or subdue aberrant inflammation. Our quantitative biology team is developing and running high-quality assays in both biochemical and cell-based formats. We provide decision-driving structure-activity-relationship (SAR) data for our team of medicinal chemists throughout the drug discovery process. We develop assays to measure pharmacodynamic (PD) response to our drugs during preclinical development. We then work to translate those assays into the clinic to understand relationship between pharmacokinetics (PK) of our drugs with that PD response (PK/PD relationship) and verify mechanism of action of our drugs in first-in-human trials. Our computational biology team works across the organization as a key part of the drug discovery and development engine at RAPT. We use both publicly-available and proprietary datasets to identify novel targets, support the biological understanding of our targets and identify patient selection strategies to increase the chance of clinical success.



FLX Bio, Inc. (Now RAPT Therapeutics, Inc.)

• Vice President of Quantitative Biology

  • Jan 2016 - Present

  South San Francisco, CA Our quantitative biology team is developing and running high quality assays in both biochemical and cell-based formats. We provide decision driving SAR data for our team of medicinal chemists throughout the drug discovery process, and pharmacodynamic data to understand PK/PD relationships.



Amgen Inc.

• United States
• Civic and Social Organizations

• Director of Research

  • Jan 2003 - Dec 2015

  South San Francisco, CA At Amgen, I lead cross-functional teams for high-throughput data generation and data mining for discovery of novel targets for drug discovery and development. I managed multiple technology-focused groups including RNAi screening, viral vector technologies, cell line engineering, genome editing, and creation of genetically-engineered rodent models. We actively evaluated new technologies for use in R&D. I collaborated across therapeutic areas and other supporting functional groups to establish… Show more At Amgen, I lead cross-functional teams for high-throughput data generation and data mining for discovery of novel targets for drug discovery and development. I managed multiple technology-focused groups including RNAi screening, viral vector technologies, cell line engineering, genome editing, and creation of genetically-engineered rodent models. We actively evaluated new technologies for use in R&D. I collaborated across therapeutic areas and other supporting functional groups to establish model systems, validate targets and select therapeutic modalities. My teams developed assays and deployed them for identification of hits and advancement of these molecules toward pre-clinical studies. Show less



Tularik

• Biotechnology Research
• 1 - 100 Employee

• Research Scientist

  • Jan 2003 - Aug 2004

  South San Francisco, CA Responsible for assay development, high throughput screening and SAR studies for small molecule drug discovery. Acquired by Amgen Inc. See above.



Pointilliste

• United States

• Director of Molecular Biology

  • Oct 2000 - May 2002

  Scientific co-founder. Developed and implemented core molecular biology and protein microarray elements of Pointilliste’s proteomics technology.



Zyomyx Inc.

• Research Scientist

  • May 1999 - Oct 2000

  Responsible for establishment of biology program within interdisciplinary company. Established high-throughput phage display-based selection and screening of antibodies.



Selective Genetics

• Research Scientist

  • Oct 1997 - May 1999

  Developed new technologies to identify protein ligands with the capacity to deliver DNA to mammalian cells.



University of California at San Diego

• United States
• Hospitals and Health Care
• 1 - 100 Employee

• Post-doctoral fellow

  • Oct 1994 - Oct 1997

  Characterized the assembly, processing and localization of the pentameric neuronal nicotinic acetylcholine receptors in primary neuronal cultures as well as transiently and stably transfected cell lines.